OR WAIT 15 SECS
Volume 50, Issue 11
Activities at the WSAVA Conference in Toronto focused on the role of nerve growth factor in pain pathway for dogs and cats.
Zoetis recently alluded to a new monoclonal antibody product in the works that could provide long-lasting osteoarthritis (OA) pain control in veterinary patients by targeting nerve growth factor (NGF) in the pain pathway. At the 2019 World Small Animal Veterinary Association (WSAVA) Conference in Toronto in July, the company supported several presentations related to research and development in chronic OA pain, according to a Zoetis release.
Highlights of Zoetis' OA-related activities at the conference included:
“We look forward to discussing the central role of NGF as a driver of osteoarthritis pain,” says Dr. Lascelles in the release. “With new approaches and a novel pain pathway on the horizon, we have an opportunity to significantly advance the way we manage osteoarthritis pain for feline and canines.”